Here are three takeaways:
1. The patents are for its lead product CybroCell, an off-the-shelf allogenic human dermal fibroblast product to treat degenerative disc disease.
2. Throughout several clinical trials, CybroCell demonstrated improved pain relief and increased back mobility in patients treated with the fibroblast.
3. SpinalCyte has 35 U.S. and foreign patents issued and 41 patents pending.
More articles on biologics:
3 things to know about Lattice Biologics’ CEO
Cellect receives patent approval for Apograft technology: 3 notes
OsteoRemedies unveils 1st FDA-cleared dual-antibiotic spacer & bone cement: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
